Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche Bank

November 12, 2013 9:25 AM EST
Get Alerts SRPT Hot Sheet
Price: $36.92 +0.44%

Rating Summary:
    13 Buy, 11 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 15 | New: 31
Trade SRPT Now!
Join SI Premium – FREE
Sarepta Therapeutic (NASDAQ: SRPT) stock fell sharply on Tuesday after the company said the FDA considers an Eteplirsen NDA "premature." In the view of Deutsche Bank analyst Robyn Karnauskas, every 1 year delay to launch impacts DCF $10 per share.

"Our sensitivities for peak Eteplirsen revenues and delay: All numbers below are at 75% probability to revenues. These market shares are in exon-51 patients only," said analyst Karnauskas.

Adjusted Peak revenues/Market share in diagnosed/Market share in all exon-51


"Timelines: we currently model early 2016 launch. Every 1 year delay impacts the DCF by $10/sh. We use 12.5% discount rate," said the analyst.

Deutsche Bank has a Buy rating on Sarepta Therapeutic with a price target of $71.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic (NASDAQ: SRPT) click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $36.56 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Hot Comments

Related Entities

Deutsche Bank

Add Your Comment